NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat cancer, infectious diseases, autoimmune diseases, asthma and dermatitis.

PRINCETON, NJ and WALTHAM, MA (October 21, 2009) – BioWa, Inc. (BioWa)

and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement
which provides NKTT with access to BioWa’s patented POTELLIGENT® Technology platform for
the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies. More>>>

GENEVA, SWITZERLAND (September 1, 2009): Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today thatthey have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M™. More>>>


WALTHAM, MA (July 27, 2009): NKT Therapeutics, Inc., a privately held biotechnology company, today announced three new appointments to the company’s scientific advisory board (SAB). More>>>